Mon, January 30, 2023
Sun, January 29, 2023
Fri, January 27, 2023
Thu, January 26, 2023

Michael Ulz Upgraded (VIR) to Hold and Increased Target to $30 on, Jan 27th, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. and-increased-target-to-30-on-jan-27th-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Michael Ulz of Morgan Stanley, Upgraded "Vir Biotechnology, Inc." (VIR) to Hold and Increased Target from $18 to $30 on, Jan 27th, 2023.

Michael has made no other calls on VIR in the last 4 months.



There are 2 other peers that have a rating on VIR. Out of the 2 peers that are also analyzing VIR, 0 agree with Michael's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Michael


  • Andrew Galler of "Morgan Stanley" Maintained at Sell with Increased Target to $18 on, Friday, November 4th, 2022
  • Joseph Stringer of "Needham" Maintained at Strong Buy with Decreased Target to $32 on, Friday, November 4th, 2022

Publication Contributing Sources